Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23671489 | 0.94 | BACE1 (0.58) | BACE1ALDH1A1ATML3MBTL1KDM4E | |
| SCHEMBL23671493 | 0.94 | BACE1 (0.58) | BACE1MEN1KMT2AALDH1A1ATM | |
| SCHEMBL23671503 | 0.92 | BACE1 (0.66) | BACE1MEN1KMT2AALDH1A1ATM | |
| SCHEMBL23671499 | 0.92 | BACE1 (0.69) | BACE1MEN1KMT2AALDH1A1ATM | |
| SCHEMBL23671496 | 0.90 | BACE1 (0.53) | BACE1ALDH1A1ATML3MBTL1KDM4E | |
| SCHEMBL23671491 | 0.88 | BACE1 (0.64) | BACE1MEN1KMT2AALDH1A1ATM | |
| SCHEMBL23671497 | 0.81 | BACE1 (0.62) | BACE1ALDH1A1ATML3MBTL1KDM4E | |
| SCHEMBL2322967 | 0.79 | HTR1B (0.67) | MEN1KMT2AALDH1A1L3MBTL1LTA4H | |
| SCHEMBL21616828 | 0.78 | TSHR (0.50) | MEN1KMT2A | |
| SCHEMBL21616841 | 0.77 | BACE1 (0.69) | BACE1LTA4HPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230131-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU) (FR) | 2021-07-29 | — | — | US | disclosed |
| EP-3820862-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020011848-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230131-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | ABCG2, SLC10A1, CYP3A43 | BACE1 1582/4885MEN1 852/4885KMT2A 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.